Stocks Health care ALGS
NASDAQ · Health careAligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. brought in $3.7M of revenue over the twelve months to June 30, 2026, up 19.4% from a year earlier. It posted a net loss of $76M. At June 30, 2026 it held $30.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Aligos Therapeutics, Inc.
- Net worth
- Aligos Therapeutics, Inc. has a market value (market cap) of $20.6M at the latest share price, and shareholders' equity of $31.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.2M (-39.5% year on year), with a net loss of $24.2M. Over the 12 months to June 30, 2026: revenue $3.7M, net loss $76M.
- Cash flow
- In fiscal 2025 operations used $82.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aligos Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Aligos Therapeutics, Inc. does
Aligos Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALGS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.2M | -$24.2M | -$2.45 | n/a |
| 2024 | $3.6M | -$131.2M | -$20.94 | -$80.9M |
| 2023 | $6.2M | -$87.7M | -$34.20 | -$79M |
| 2022 | $0 | -$96M | -$56.58 | -$80.3M |
| 2021 | $0 | -$128.3M | -$80.97 | -$116.6M |
| 2020 | $0 | -$108.5M | -$273.35 | -$76.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ALGS ranks in Health care
Latest SEC filings
What Aligos Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026
- August 6, 2026
- August 6, 2026
- August 6, 2026
- June 26, 2026
- June 24, 2026Activist stake (5% or more) SCHEDULE 13D
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 810% to $2.8M versus the same quarter last year; diluted EPS -$2.21 versus -$2.11.
- May 7, 2026
Insider trades
What the people running Aligos Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns ALGS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 9.99% | May 15, 2025 |
| Lawrence M. Blatt13D, may seek influence | 5.6% | June 24, 2026 |
| Sio Capital Management, LLC13G, passive | 5.46% | February 11, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 31 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Deep Track Capital, LP | 444,110 | 0 |
| Alyeska Investment Group, L.P. | 412,000 | 0 |
| Sio Capital Management, LLC | 327,237 | 0 |
| Marshall Wace, Llp | 246,579 | -20,556 |
| Woodline Partners LP | 177,362 | 0 |
| Vanguard Capital Management LLC | 175,543 | -2,719 |
| Baker Bros. Advisors LP | 83,055 | 0 |
| Hhlr Advisors, Ltd. | 76,247 | 0 |
| D. E. Shaw & Co., Inc. | 66,463 | +55,485 |
| UBS Group AG | 59,986 | +22,925 |
| Geode Capital Management, LLC | 47,173 | -2,802 |
| Jane Street Group, LLC | 32,402 | new |
| BlackRock, Inc. | 30,292 | +17,252 |
| Vanguard Fiduciary Trust Co | 28,612 | +175 |
| Dimensional Fund Advisors LP | 21,044 | new |
| Verition Fund Management LLC | 18,887 | 0 |
| Trexquant Investment LP | 12,339 | new |
| Renaissance Technologies LLC | 10,800 | -89,650 |
| Rockefeller Capital Management L.P. | 10,000 | 0 |
| Federation des caisses Desjardins du Quebec | 4,650 | +3,700 |
Insiders
Questions about ALGS
What does Aligos Therapeutics, Inc. do?
Aligos Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ALGS. Its shares trade on NASDAQ under the ticker ALGS.
What is Aligos Therapeutics, Inc.'s net worth?
Aligos Therapeutics, Inc. has a market value (market cap) of $20.6M at the latest share price, and shareholders' equity of $31.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Aligos Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $76M on revenue of $3.7M.
How much revenue does Aligos Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Aligos Therapeutics, Inc. reported revenue of $3.7M. That is 19.4% more than a year earlier.
When did Aligos Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 15, 2026.
When is Aligos Therapeutics, Inc.'s next earnings report?
Aligos Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare ALGS with
Follow ALGS
Get an email when Aligos Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aligos Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.